Related Experiment Video
Updated: Jul 17, 2026
08:18
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
Norlignans with Hyaluronidase Inhibitory Activity from Anemarrhena asphodeloides
Planta Medica
|January 30, 2007
Summary
Two norlignans from Anemarrhena asphodeloides Bunge, including a new compound, showed hyaluronidase inhibitory activity. These findings highlight potential natural inhibitors for therapeutic applications.
Area of Science:
- Natural Product Chemistry
- Pharmacognosy
- Biochemistry
Background:
- Anemarrhena asphodeloides Bunge is a medicinal plant with various bioactive compounds.
- Hyaluronidase is an enzyme involved in connective tissue degradation, making its inhibitors potential therapeutic agents.
Purpose of the Study:
- To isolate and identify compounds from Anemarrhena asphodeloides Bunge with hyaluronidase inhibitory activity.
- To characterize a newly discovered norlignan with potential biological effects.
Main Methods:
- Assay-guided fractionation of a methanol extract from Anemarrhena asphodeloides Bunge.
- Chemical structure elucidation of isolated compounds using spectroscopic methods.
- In vitro hyaluronidase inhibition assays.
Main Results:
- Two norlignans, CIS-hinokiresinol (1) and 1,3-di-P-hydroxyphenyl-4-penten-1-one (2), were isolated and identified.
- Compound 2, a new norlignan, demonstrated hyaluronidase inhibitory activity.
- An inactive norlignan, 4'-methyl-CIS-hinokiresinol (3), was also identified.
Conclusions:
- Anemarrhena asphodeloides Bunge contains norlignans with significant hyaluronidase inhibitory potential.
- The newly identified compound, 1,3-di-P-hydroxyphenyl-4-penten-1-one, represents a novel hyaluronidase inhibitor.
- Further research into these compounds may lead to the development of new therapeutic strategies.
Related Concept Videos
00:55Nitriles to Amines: LiAlH4 Reduction
Nitriles are reduced to amines in the presence of strong reducing agents like lithium aluminum hydride through a typical nucleophilic acyl substitution. The reaction requires two equivalents of the reducing agent. The reducing agent acts as a source of hydride ions.
As shown below, the mechanism involves three steps. Firstly, the hydride ion acting as a nucleophile attacks the nitrile carbon to form an anion. In the second step, a second equivalent of the hydride ion attacks the anion to...
As shown below, the mechanism involves three steps. Firstly, the hydride ion acting as a nucleophile attacks the nitrile carbon to form an anion. In the second step, a second equivalent of the hydride ion attacks the anion to...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...